ABSTRACT Eighty-two patients with histologically confirmed lung cancer were randomly allocated to leceive either radiotherapy alone (2400-3200 rads, depending upon cell type) or the same dose of radiotherapy followed by four cycles of adriamycin and 5-fluorouracil. Eighty-one patients were evaluated and for the group as a whole survival was better in the group receiving adjuvant chemotherapy. Within cell types survival was better in the undifferentiated group assigned to receive adjuvant chemotherapy but survival in the patients with squamous tumours was not significantly prolonged. The chemotherapy was not unduly toxic.
In bronchogenic carcinoma adjuvant chemotherapy might prolong survival by shrinking or ,ablating tumour deposits both within the chest and in non-irradiated extrathoracic organs. In this study we compared the survival rate in patients with a bronchogenic carcinoma who were randomly allocated to receive either radiotherapy alone or radiotherapy followed by four cycles of adriamycin and 5-fluorouracil.
Methods
Eighty-two patients with a histologically confirmed bronchogenic carcinoma confined to the thorax were studied. They were all considered suitable for treatment by radical radiotherapy. The following cell types were recognised: squamous cell, small cell, adenocarcinoma, and undifferentiated tumours. Where it was impossible to determine the cell of origin the type was classified as "unspecified". Patients were excluded from the study if they had co-existent serious general disease.
Before treatment patients had a chest radiograph, blood urea, haemoglobin, white blood cell count, and liver function tests. Radioactive The survival rates for all the patients are shown in the figure. These were calculated using the product limit method' and the time was measured from the first day of treatment. The patients still alive at the time of analysis in the radiotherapy group had survived one, seven, nine, 10, 22, 63, 83, and 94 weeks and in the adjuvant group 11, 2, 56, 59, 118, and 163 weeks. The figure shows the improved survival in the adjuvant group particularly after the completion of chemotherapy.
The survival data were analysed using a log rank test2 (table 2) , and for these tests the patients were subdivided according to the main features expected to affect their prognosis-namely, histological type and presence of mediastinal nodes. The overall effect of chemotherapy was determined by summating the observed and expected numbers of deaths, calculating x2 for these sums and referring to standard tables with one degree of freedom. This yielded a p value of-002. For patients with undifferentiated tumours the observed difference in survival was almost double that shown in -|00- 
Discussion
Earlier studies of adjuvant chemotherapy with radiotherapy have yielded conflicting results. When radiotherapy in tumour doses of 4000-5000 rads was added to nitrogen mustard,3 vinblastine,4 or procarbazine5 there was no improvement in survival but these drugs are relatively ineffective in lung cancer. Carr et a16 studied 188 patients with a variety of histological types of lung cancer who were allocated to receive 4500-5000 rads of radiotherapy alone or the same tumour dose combined with 5-fluorouracil 10 mg/kg iv daily for five days. Survival was not improved in the adjuvant group for any cell type. Almost all these patients developed irradiation oesophagitis and the majority of those receiving chemotherapy showed toxic drug reactions. It is possible that any benefit from the chemotherapy might have been masked by deaths from the combination of the large doses of radiotherapy and chemotherapy. Another study7 showed that tumour regression in a group of lung cancer patients was equivalent in patients given 2000 rads plus 5-fluorouracil to those given 4000 rads alone while regression in both groups was better than in a third group receiving 2000 rads alone. This study failed to show any benefit on survival from giving 5-fluorouracil. A recent Medical Research 
